A Study of the Safety, Tolerability, and Absorption, Metabolism, and Excretion of PA-824 in Healthy Adult Male Subjects. (CL-004)
2018年8月1日 更新者:Global Alliance for TB Drug Development
A Phase 1, Open-Label, Single-Dose Study of the Safety, Tolerability, and Absorption, Metabolism, and Excretion of [14C]-PA 824 in Healthy Adult Male Subjects.
This study is a Phase 1, single-center, open-label, single-dose study to evaluate (1) the absorption, metabolism, and excretion patterns of a single dose of [14C] PA-824, and (2) the pharmacokinetics, safety, and tolerability of a single oral-suspension dose of unlabeled PA-824 in healthy adult male subjects.
Unlabeled PA-824 and [14C]-PA-824 will be administered together in an oral-suspension formulation.
Enrollment is planned for one dose group of 6 subjects.
All 6 subjects will receive the same treatment.
研究概览
研究类型
介入性
注册 (实际的)
6
阶段
- 阶段1
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
Wisconsin
-
Madison、Wisconsin、美国、53704
- Covance Clinical Research Unit
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
19年 至 50年 (成人)
接受健康志愿者
不
有资格学习的性别
男性
描述
Inclusion Criteria:
- Be healthy non-tobacco/nicotine using (6-month minimum) adult male subjects, 19 to 50 years of age, inclusive
- Weigh within 20% of their ideal weights (Table of "Desirable Weights of Adults", Metropolitan Life Insurance Company, 1999)
- Be medically healthy subjects with clinically insignificant Screening results (among laboratory profiles, medical histories, ECGs, or physical exam), as deemed by the Principal Investigator in consultation with the Sponsor Medical Monitor.
- Have a history of regular bowel movements (5-6 movements week, ideally 1 per day), as deemed by the Principal Investigator in consultation with the Sponsor Medical Monitor.
- Have negative urinalysis test results for drugs of abuse such as amphetamines, cannabinoids, and cocaine metabolites
- Have the ability to understand the requirements of the study, have provided written informed consent (as evidenced by signature on an informed consent document approved by an IRB), and agree to abide by the study restrictions
Exclusion Criteria:
- Any acute illness or history or presence of significant (as deemed by the Principal Investigator) cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease
- Any preexisting condition that would interfere with normal anatomy or function of the gastrointestinal tract.
- Any medical condition that would interfere with radiocarbon assessments.
- Any serum creatinine or BUN measure beyond the upper limit of the normal range at Screening or Check-in.
- Positive Screening test for HCV, HBV, or HIV
- History of peptic ulcer disease, gastritis, esophagitis, or gastroesophageal reflux disease
- History of any cardiac abnormality (as deemed by the Principal Investigator)
- History of hypokalemia or hypomagnesemia
- History of prolonged QT interval
- Family history of Long-QT Syndrome or sudden death
- Resting pulse rate < 40 or > 100 bpm at both Screening and Check-in
- QTc interval > 430 msec as documented at Screening and Baseline (Check-in) ECG
- History or presence of alcoholism or drug abuse within the past year (as deemed by the Principal Investigator)
- Use of alcohol within 72 hours prior to dosing
- Significant history of drug and/or food allergies (as deemed by the Principal Investigator)
- Use of any prescription medication within 14 days prior to dosing or during the study
- Use of any over-the-counter medication including vitamins, herbal preparations, antacids, cough and cold remedies, etc., within 7 days prior to dosing or during the study
- Use of any drugs or substances within 30 days prior to dosing known to be strong inhibitors or inducers of cytochrome P450 enzymes or known to prolong the QT interval
- Consumption of products containing grapefruit within 10 days prior to dosing
- Any special dietary changes during the 30 days prior to dosing, as deemed by the Principal Investigator in consultation with the Sponsor Medical Monitor
- Any strenuous exercise within 1 week of Check-in, as deemed by the Principal Investigator in consultation with the Sponsor Medical Monitor
- Known allergies to Na CMC or DMSO, components of the formulation to be used in this study
- Current employment in a job requiring radiation-exposure monitoring
- Participation in any study involving radioactivity within the last 12 months
- More than one X-ray greater than the equivalent of one routine chest X-ray or one routine dental X-ray in the past 12 months
- Donation of whole blood within 56 days prior to dosing
- Plasma donation within 7 days prior to dosing
- Participation in another clinical trial within 30 days prior to dosing
- Hemoglobin < 12.0 g/dL
- Previous use of PA-824
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:PA-824
[14C]-PA-824 and unlabelled PA-824 oral suspension of 1000 mg unlabeled micronized PA-824 mixed with sufficient [14C]-PA-824 to achieve a final radiolabel dose of approximately 100 µCi/dose.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Characterize the plasma pharmacokinetic variable area under the curve of a single oral-suspension dose of PA-824.
大体时间:Days 0-12
|
Characterize the plasma pharmacokinetics of a single oral-suspension dose of PA-824 in healthy adult male subjects by calculating the variable area under the curve [AUC (0-t)] from total PA-824 plasma concentrations.
|
Days 0-12
|
Characterize the plasma pharmacokinetic variable maximum concentration of a single oral-suspension dose of PA-824.
大体时间:Days 0-12
|
Characterize the plasma pharmacokinetics of a single oral-suspension dose of PA-824 in healthy adult male subjects by calculating the variable maximum plasma concentration (Cmax) from total PA-824 plasma concentrations.
|
Days 0-12
|
Characterize the plasma pharmacokinetic variable time to peak plasma concentration of a single oral-suspension dose of PA-824.
大体时间:Days 0-12
|
Characterize the plasma pharmacokinetics of a single oral-suspension dose of PA-824 in healthy adult male subjects by calculating the variable time to peak plasma concentration (Tmax) from total PA-824 plasma concentrations.
|
Days 0-12
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
The frequency and severity of treatment related adverse events throughout the study.
大体时间:Days 0 -12
|
In order to evaluate the safety and tolerability of a single oral-suspension dose of PA-824 in healthy adult male subjects
|
Days 0 -12
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 首席研究员:William Bridson, MD、Covance CRU
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始
2006年3月1日
初级完成 (实际的)
2006年5月1日
研究完成 (实际的)
2006年5月1日
研究注册日期
首次提交
2017年6月1日
首先提交符合 QC 标准的
2017年6月27日
首次发布 (实际的)
2017年6月28日
研究记录更新
最后更新发布 (实际的)
2018年8月2日
上次提交的符合 QC 标准的更新
2018年8月1日
最后验证
2018年2月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
PA-824的临床试验
-
Global Alliance for TB Drug Development完全的
-
National Institute of Allergy and Infectious Diseases...尚未招聘
-
Bayer完全的甲型血友病比利时, 新西兰, 荷兰, 希腊, 英国, 奥地利, 美国, 意大利, 罗马尼亚, 保加利亚, 加拿大, 以色列, 波兰, 立陶宛, 挪威, 阿根廷, 西班牙
-
Global Alliance for TB Drug Development完全的